
Current Positions
- Director, Program Management – Population Health Research Institute
Bio
Jackie started working with this group in 1993, as she was completing her Masters in Clinical Epidemiology, with the intent to learn how to do clinical trials so she could run trials in post-stroke rehabilitation. Since that time Jackie has acted in the Co-ordinator, Program Manager and most recently, Co-investigator on many large trials in both primary and secondary prevention of cardiovascular disease and diabetes. Through these activities, Jackie developed an active interest in both trial methodology and process and participates in national and international initiatives to improve the design and conduct of clinical trials. She is also an Associate Professor at the School of Rehabilitation Science, where she teaches a variety of courses including Evidence Based Practice.
Most recently, Jackie’s research interest have focussed on understanding the causes of functional decline as well as developing simple, internationally applicable interventions to improve post-stroke disability. Jackie has over 65 peer reviewed publications and has received awards such as Contribution to the School of Rehabilitation Science award at McMaster and the President’s Award for outstanding Service. and the PHRI award for Outstanding Contributions to Global Collaborations.
Publications are listed in chronological order by descending date. Link takes user to pubMed for publication details.
-
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.
Source: N Engl J Med -
Does Lowering Blood Pressure With Antihypertensive Therapy Preserve Independence in Activities of Daily Living? A Systematic Review.
Source: Am J Hypertens -
The mini-mental state examination, clinical factors, and motor vehicle crash risk.
Source: J Am Geriatr Soc -
Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
Source: Lancet Diabetes Endocrinol -
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.
Source: Diabetologia -
Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial.
Source: Int J Cardiol -
Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.
Source: Eur Heart J -
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
Source: Diabetes Care -
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes.
Source: Anesthesiology -
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
Source: Eur Heart J -
Randomized clinical trials–removing unnecessary obstacles.
Source: N Engl J Med -
Setting the record straight on TIDE: a lost opportunity for patients with diabetes.
Source: Diabetologia -
Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study.
Source: Diabetes Care -
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).
Source: Diabetes Care -
Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis.
Source: Am Heart J -
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery.
Source: JAMA -
Basal insulin and cardiovascular and other outcomes in dysglycemia.
Source: N Engl J Med -
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Source: N Engl J Med -
Cognitive impairment and risk of cardiovascular events and mortality.
Source: Eur Heart J -
Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies.
Source: CMAJ -
The fluid study protocol: a randomized controlled study on the effects of bioimpedance analysis and vitamin D on left ventricular mass in peritoneal dialysis patients.
Source: Perit Dial Int -
The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.
Source: Circulation -
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Source: J Am Coll Cardiol -
Lipid lowering for primary prevention.
Source: Lancet -
Specific barriers to the conduct of randomized trials.
Source: Clin Trials -
Sensible guidelines for the conduct of large randomized trials.
Source: Clin Trials -
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
Source: Am Heart J -
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.
Source: Eur Heart J -
Independent design and conduct of clinical trials.
Source: Clin Trials -
Effect of ramipril on the incidence of diabetes.
Source: N Engl J Med -
Home and community occupational therapy for children and youth: a before and after study.
Source: Can J Occup Ther -
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
Source: Circulation -
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.
Source: JAMA -
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease.
Source: Am Heart J -
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
Source: Circulation -
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.
Source: J Am Coll Cardiol -
Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study.
Source: Kidney Int -
Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.
Source: Eur J Cardiovasc Prev Rehabil -
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
Source: Circulation -
Preventing stroke with ramipril–authors’ reply.
Source: BMJ -
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.
Source: Diabetes Care -
Effect of long-term therapy with ramipril in high-risk women.
Source: J Am Coll Cardiol -
Use of ramipril in preventing stroke: double blind randomised trial.
Source: BMJ